Single-Dose Zilebesiran Cuts BP Out to 6 Months: KARDIA-2

Source link :

Treatment with a single subcutaneous dose of the RNA interference agent zilebesiran was associated with clinically significant reductions in systolic blood pressure compared with placebo at 3 months when added to a standard antihypertensive therapy in the KARDIA-2 study. These differences were maintained to 6 months in most patients, despite add-on antihypertensive therapy. In terms […]

Author : News Health

Publish date : 2024-04-15 07:57:24

Copyright for syndicated content belongs to the linked Source.